Provectus Biopharmaceuticals, Inc. announced the launch of VisiRose, Inc., its first Founded Entity, a new clinical-stage biotechnology company. VisiRose is focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for infectious keratitis and other serious eye infections.
RB PDAT is an investigational treatment developed from innovative ocular research at the University of Miami's Bascom Palmer Eye Institute. The therapy combines Provectus's pharmaceutical-grade Rose Bengal Sodium (RBS) active pharmaceutical ingredient with a light-based medical device to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.
Clinical trials across the U.S., India, Brazil, and Mexico involving over 500 patients have shown promising results for RB PDAT, demonstrating rapid infection resolution and improved patient outcomes. VisiRose aims to address a significant gap in the $60 billion global ophthalmic market, particularly in regions impacted by rising antimicrobial resistance and limited access to effective treatments.
Ed Pershing, Chairman of both VisiRose and Provectus, stated that VisiRose exemplifies Provectus's business model, bridging innovation and impact while unlocking value for stockholders. Dominic Rodrigues, Acting CEO of VisiRose and President/Vice Chairman of Provectus, highlighted RB PDAT as a consequential solution for patients at risk of vision loss from infectious keratitis.
This strategic spin-off enhances Provectus's ability to address unmet medical needs and maximize the intrinsic value of its proprietary RBS platform. The University of Miami is a minority equity shareholder of VisiRose.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.